Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell-Derived Cardiomyocytes

S. Klimovic, M. Scurek, M. Pesl, D. Beckerova, S. Jelinkova, T. Urban, D. Kabanov, Z. Starek, M. Bebarova, J. Pribyl, V. Rotrekl, K. Brat

. 2021 ; 12 (-) : 789730. [pub] 20220117

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010227

Grantová podpora
NU20-06-00156 MZ0 CEP - Centrální evidence projektů

Cardiac side effects of some pulmonary drugs are observed in clinical practice. Aminophylline, a methylxanthine bronchodilator with documented proarrhythmic action, may serve as an example. Data on the action of aminophylline on cardiac cell electrophysiology and contractility are not available. Hence, this study was focused on the analysis of changes in the beat rate and contraction force of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and HL-1 cardiomyocytes in the presence of increasing concentrations of aminophylline (10 μM-10 mM in hPSC-CM and 8-512 μM in HL-1 cardiomyocytes). Basic biomedical parameters, namely, the beat rate (BR) and contraction force, were assessed in hPSC-CMs using an atomic force microscope (AFM). The beat rate changes under aminophylline were also examined on the HL-1 cardiac muscle cell line via a multielectrode array (MEA). Additionally, calcium imaging was used to evaluate the effect of aminophylline on intracellular Ca2+ dynamics in HL-1 cardiomyocytes. The BR was significantly increased after the application of aminophylline both in hPSC-CMs (with 10 mM aminophylline) and in HL-1 cardiomyocytes (with 256 and 512 μM aminophylline) in comparison with controls. A significant increase in the contraction force was also observed in hPSC-CMs with 10 μM aminophylline (a similar trend was visible at higher concentrations as well). We demonstrated that all aminophylline concentrations significantly increased the frequency of rhythm irregularities (extreme interbeat intervals) both in hPSC-CMs and HL-1 cells. The occurrence of the calcium sparks in HL-1 cardiomyocytes was significantly increased with the presence of 512 μM aminophylline. We conclude that the observed aberrant cardiomyocyte response to aminophylline suggests an arrhythmogenic potential of the drug. The acquired data represent a missing link between the arrhythmic events related to the aminophylline/theophylline treatment in clinical practice and describe cellular mechanisms of methylxanthine arrhythmogenesis. An AFM combined with hPSC-CMs may serve as a robust platform for direct drug effect screening.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010227
003      
CZ-PrNML
005      
20220425131749.0
007      
ta
008      
220420s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2021.789730 $2 doi
035    __
$a (PubMed)35111056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Klimovic, Simon $u CEITEC, Masaryk University, Brno, Czechia $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czechia
245    10
$a Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell-Derived Cardiomyocytes / $c S. Klimovic, M. Scurek, M. Pesl, D. Beckerova, S. Jelinkova, T. Urban, D. Kabanov, Z. Starek, M. Bebarova, J. Pribyl, V. Rotrekl, K. Brat
520    9_
$a Cardiac side effects of some pulmonary drugs are observed in clinical practice. Aminophylline, a methylxanthine bronchodilator with documented proarrhythmic action, may serve as an example. Data on the action of aminophylline on cardiac cell electrophysiology and contractility are not available. Hence, this study was focused on the analysis of changes in the beat rate and contraction force of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and HL-1 cardiomyocytes in the presence of increasing concentrations of aminophylline (10 μM-10 mM in hPSC-CM and 8-512 μM in HL-1 cardiomyocytes). Basic biomedical parameters, namely, the beat rate (BR) and contraction force, were assessed in hPSC-CMs using an atomic force microscope (AFM). The beat rate changes under aminophylline were also examined on the HL-1 cardiac muscle cell line via a multielectrode array (MEA). Additionally, calcium imaging was used to evaluate the effect of aminophylline on intracellular Ca2+ dynamics in HL-1 cardiomyocytes. The BR was significantly increased after the application of aminophylline both in hPSC-CMs (with 10 mM aminophylline) and in HL-1 cardiomyocytes (with 256 and 512 μM aminophylline) in comparison with controls. A significant increase in the contraction force was also observed in hPSC-CMs with 10 μM aminophylline (a similar trend was visible at higher concentrations as well). We demonstrated that all aminophylline concentrations significantly increased the frequency of rhythm irregularities (extreme interbeat intervals) both in hPSC-CMs and HL-1 cells. The occurrence of the calcium sparks in HL-1 cardiomyocytes was significantly increased with the presence of 512 μM aminophylline. We conclude that the observed aberrant cardiomyocyte response to aminophylline suggests an arrhythmogenic potential of the drug. The acquired data represent a missing link between the arrhythmic events related to the aminophylline/theophylline treatment in clinical practice and describe cellular mechanisms of methylxanthine arrhythmogenesis. An AFM combined with hPSC-CMs may serve as a robust platform for direct drug effect screening.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Scurek, Martin $u Department of Respiratory Diseases, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Pesl, Martin $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u First Department of Internal Medicine-Cardioangiology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Brno, Czechia
700    1_
$a Beckerova, Deborah $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Jelinkova, Sarka $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Urban, Tomas $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u First Department of Internal Medicine-Cardioangiology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Brno, Czechia
700    1_
$a Kabanov, Daniil $u CEITEC, Masaryk University, Brno, Czechia $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czechia
700    1_
$a Starek, Zdenek $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u First Department of Internal Medicine-Cardioangiology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Brno, Czechia
700    1_
$a Bebarova, Marketa $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Pribyl, Jan $u CEITEC, Masaryk University, Brno, Czechia
700    1_
$a Rotrekl, Vladimir $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 12, č. - (2021), s. 789730
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35111056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131746 $b ABA008
999    __
$a ind $b bmc $g 1784528 $s 1161425
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 789730 $e 20220117 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
GRA    __
$a NU20-06-00156 $p MZ0
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace